This excerpt taken from the TPTX 8-K filed Jun 30, 2005.
New York, NY June 30, 2005 Axonyx Inc. (NASDAQ: AXYX) a U.S.-based biopharmaceutical company, today announced that Marvin S. Hausman, MD, has elected to step down as Chairman on September 14, 2005 but will remain a director of Axonyx. The board of directors unanimously elected Steven B. Ratoff as non-executive chairman to succeed Dr. Hausman.
Dr. Hausman founded Axonyx in 1997 and was instrumental in identifying and licensing - the technologies which are the basis of the companys current focus. Dr. Hausman is Chairman of Oxis International (OXIS: OB), in which the company owns a 34% interest. He is also a Director of Arbios Systems Inc. (ABOS: OB), a liver dialysis company. Dr. Hausmans scientific/clinical expertise and interests also include cancer immunology, organ transplantation and infectious diseases.
The Company has entered into a consulting agreement with Dr. Hausman that will provide it with continued access to Dr. Hausmans considerable knowledge and experience.
Steven B. Ratoff, a seasoned business executive, joined the Axonyx board on May 5, 2005. Mr. Ratoff is currently a private investor and a Venture Partner with Proquest Investments, a biopharmaceutical venture capital firm. He most recently served as Chairman and Interim Chief Executive Officer of Cima Labs, Inc., a public specialty pharmaceutical company, from May 2003 through its sale to Cephalon, Inc. in August 2004. Mr. Ratoff is currently a director of InKine Pharmaceutical Company, Inc. (NASDAQ: INKP).
I remain committed to Axonyx and to the attainment of its clinical goals, said Dr. Hausman. I have great confidence in Stevens track record of success in the biopharmaceutical industry and believe the right team is in place to move our company forward.
Commenting on the transition, Gosse B Bruinsma, MD, President and CEO of Axonyx stated We are very appreciative of Marvins efforts and experience in growing and financing the company since its inception in 1997 and look forward to continuing our
relationship. We look forward to working with Steven and benefiting from his leadership as we continue to develop our CNS pipeline.
This excerpt taken from the TPTX 8-K filed May 5, 2005.
New York, NY May 5, 2005 Axonyx Inc. (NASDAQ: AXYX), a U.S.-based biopharmaceutical company, today announced the appointment of Steven B. Ratoff to its Board of Directors, effective immediately. Mr. Ratoff replaces Michael A. Griffith, who resigned from the Board on April 29, 2005 in order to fully pursue a new business venture he is leading. Axonyx currently has seven board members, of which five are outside, independent directors.
We appreciate Mikes contributions to the Company during his tenure with us and wish him the very best in his new venture, stated Marvin S. Hausman, M.D., Chairman of the Company. We are also very pleased to welcome Steven Ratoff to our Board. Stevens extensive background as a chief executive officer of two life sciences companies, as well as the breath and depth of his finance experience, makes him a valuable addition to our Board.
Mr. Ratoff is currently a private investor and a Venture Partner with Proquest Investments, a biopharmaceutical venture capital firm. He most recently served as Chairman and Interim Chief Executive Officer of Cima Labs, Inc., a public specialty pharmaceutical company, from May 2003 through its sale to Cephalon, Inc. in August 2004.
He was the President and Chief Executive Officer of MacroMed, Inc., a privately owned drug delivery company, from February 2001 to December 2001, and also as director since 1998.
Mr. Ratoffs experience includes serving as Executive Vice President and Chief Financial Officer of Brown-Forman Corporation, a public diversified manufacturer of consumer products, as well as fifteen years in a variety of senior financial positions with Bristol-Myers Squibb.
Mr. Ratoff is currently a director of InKine Pharmaceutical Company, Inc. (NASDAQ: INKP).